Abstract. Recent studies have revealed a positive therapeutic effect of dihydroartemisinin (DHA) on tumor cells. However, the underlying mechanism of this has not yet been elucidated. The present study examined the potential therapeutic role and mechanism of DHA in T-cell lymphoma cells. It was revealed that DHA inhibited the proliferation of Jurkat and HuT-78 T-cell lymphoma cells in a concentration-and time-dependent manner. Furthermore, DHA reduced c-Myc protein expression at the transcriptional level, and induced the phosphorylation of c-Myc and the degradation of c-Myc oncoprotein levels. DHA treatment resulted in decreased phosphorylation of protein kinase B (Akt) and glycogen synthase 3β (GSK3β) in T-cell lymphoma cells. In addition, DHA treatment induced cell apoptosis, which was accompanied by an increased ratio of Bax/Bcl-2. Taken together, the results of the present study suggested that DHA may exert its antitumor role by accelerating c-Myc proteolysis and inhibiting the Akt/GSK3β pathway in T-cell lymphoma cells.
Introduction
T-cell lymphoma accounts for 9.7% of all lymphoid malignancies, with an incidence rate of 1.17 cases per 100,000 people in Hong Kong (1) . T-cell lymphoma has distinct clinical features and a complicated epidemiology (2) . Despite treatment with intensive chemotherapy or combined chemotherapy, patients with T-cell lymphoma continue to exhibit suboptimal outcomes and a poor disease progression (3, 4) . The development of effective therapeutic treatments to improve the prognosis of T-cell lymphoma is required.
The c-Myc transcription factor is a short-lived nuclear phosphoprotein that serves a vital role in regulating cell proliferation, differentiation and apoptosis (5, 6) . Notably, overexpression of c-Myc has been associated with the occurrence of hematopoietic malignancies, including lymphoma and leukemia (7) . Glycogen synthase kinase 3β (GSK3β) regulates c-Myc levels and activity by phosphorylating c-Myc at threonine 58 to promote its degradation by the ubiquitin-proteasome pathway in lymphoma (8) . A previous study in acute lymphocytic leukemia cells revealed that GSK3β exhibits a low affinity to the stabilized c-Myc oncoprotein (7) . Taken together, these results suggested that downregulation of c-Myc expression may be an effective strategy for the treatment of lymphoma.
The phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt)/GSK3β signaling pathway serves important regulatory roles in differentiation, cell survival and apoptosis (9) . Akt is a critical downstream factor of PI3K and is activated through PI3K phosphorylation of Akt at serine 473 (10) . Phosphorylated Akt (p-Akt) subsequently activates GSK3β, its principal physiological substrate, by phosphorylation of GSK3β at serine 9 (10) . Activated Akt supported a survival signal by phosphorylating apoptotic factors, including GSK3β, and preventing cells from apoptosis (9, 11, 12) . Previous studies have revealed that the Akt/GSK3β signaling pathway is activated to promote cell proliferation and decrease apoptosis in various types of carcinoma (13) . The function of the p-Akt/GSK3β pathway is to promote proliferation and to decrease apoptosis. p-Akt is involved in tumor proliferation and a poor prognosis in several types of human cancer, and it may be an important factor in the development of lymphomas (14, 15) .
Dihydroartemisinin (DHA) is a compound isolated from Artemisia annua L, a Chinese medicinal herb. A few reports, including our previous study, indicated DHA as a promising drug for tumor therapy due to its antitumor activity in cancer cells (16) (17) (18) threonine 58 (19) . DHA also suppressed cell proliferation via the Akt/GSK3β/cyclin D1 signaling pathway in A549 lung cancer cells and promoted the degradation of c-Myc via increased phosphorylation of c-Myc (19, 20) . Based on these studies, we hypothesized that DHA exhibits antiproliferation activity in T-cell lymphoma cells and that DHA may mediate c-Myc oncoprotein degradation and downregulate the Akt/GSK3β signaling pathway in T-cell lymphoma cells. Therefore, the present study examined the potential anticancer effect of DHA on T-cell lymphoma cells (Jurkat and HuT-78 cells). We also investigated the underlying mechanism of DHA was also investigated in T-cell lymphoma cells and the potential involvement of the AKT/GSK3β signaling pathway. This study may provide evidence for DHA as a possible treatment for T-cell lymphoma cells.
Materials and methods
Materials and cell culture. DHA was obtained from Chunyou Biological Technology Corporation (Shanghai, China) and dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) as a stock solution of 8,000 µM at -20˚C. RPMI-1640 medium (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) was used to dilute the stocked DHA for each experiment.
T-cell lymphoma Jurkat and HuT-78 cell lines were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Jurkat cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), and HuT-78 cells were cultured in Iscove's modified Dulbecco's medium (Hyclone; GE Healthcare Life Sciences) containing 20% fetal bovine serum. Medium was supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin and 2.5 mg/ml amphotericin B, and cells were incubated at 37˚C in a humidified 5% CO 2 atmosphere. The control group comprised cells not exposed to DHA, while the DHA group comprised cells treated with DHA.
Cell viability assay. Cell viability assay was evaluated using Cell Counting kit-8 (CCK-8; Anhui Yiyuan Biotechnology Co., Ltd., Anhui, China). Jurkat cells were seeded at a density of 8x10 3 cells/well in 100 µl RPMI-1640 medium supplemented with 10% fetal bovine serum and HuT-78 cells were seeded at a density of 8x10 3 cells/well in 100 µl Iscove's modified Dulbecco's medium containing 20% fetal bovine serum in a 96-well plate (Costar; Corning Incorporated, Corning, NY, USA), and the cells were incubated for 24, 36, 48, 60 or 72 h with DHA (0, 5, 10, 20, 40 or 80 µM) added to the culture medium. At each time point, 10 µl CCK-8 was added to each well and the cells were subsequently incubated at 37˚C for 2 h. Absorbance was detected at 450 nm on a microplate absorbance reader (Sunrise; Tecan Group Ltd., Männedorf, Switzerland).
Cell apoptosis assay. Jurkat (1x10 6 ) were seeded onto a 6-well plate with 2 ml RPMI-1640 medium supplemented with 10% fetal bovine serum and HuT-78 (1.5x10 6 ) cells were seeded onto a 6-well plate with 2 ml Iscove's modified Dulbecco's medium containing 20% fetal bovine serum followed by incubation at 37˚C for 48 h. Subsequently, DHA (0 or 15 µM for Jurkat cells and 0 or 30 µM for HuT-78 cells) was added. All cells were resuspended with cold PBS (Hyclone; GE Healthcare Life Sciences) and centrifuged at 447.2 x g for 5 min at room temperature. Cells were resuspended in 300 µl cold binding buffer (BD Biosciences, Franklin Lakes, NJ, USA) following the addition of 5 µl Annexin V-fluorescein isothiocyanate (BD Biosciences) for 15 min in the dark at room temperature. Propidium iodide (PI; 5 µl; BD Biosciences) was added and incubated for another 5 min, and another 200 µl binding buffer was added, followed by a flow cytometer (BD Biosciences) FlowJo software version 7.6.1 (FlowJo LLC, Ashland, OR, USA) being used to analyze each sample.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was extracted from the cultured cells using RNAiso Plus (Takara Bio, Inc., Otsu, Japan), according to the manufacturer's protocol. Pectrophotometry (Dynamica Scientific Ltd., Newport Pagnell, UK) was used to determine the quality and quantity of RNA. Total RNA was reverse transcribed into single-stranded cDNA using a Prime Script™ RT reagent kit (Takara Bio, Inc.), according to the manufacturer's protocols. Next, the reverse transcribed single-stranded cDNA was amplified by SYBR1 Premix Ex Taq II (Takara Bio, Inc.) with a CFX96 spectrofluorometric thermal cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The primers were synthesized by Tsingke Biological Technology Co., Ltd. (Beijing, China; Table I ). Thermocycling conditions included a pre-incubation stage at 95˚C for 30 sec, and 40 cycles of amplification stage at 95˚C for 5 sec and 60˚C for 30 sec, and a melt curve stage at 95˚C for 15 sec, 65˚C for 60 sec and 95˚C for 15 sec. Relative expression of GAPDH mRNA was used as an endogenous internal control. Gene expression changes was assessed with the 2 -ΔΔCq method (21) . 
Results

DHA decreases the viability of Jurkat and HuT-78 cells.
The present study first evaluated the effects of DHA on the proliferation of the T-cell lymphoma Jurkat and HuT-78 cell Fig. 2A and B). The mRNA and protein expression levels of Bax and Bcl-2 were also evaluated by RT-qPCR and western blot analysis. In the two cell lines, Bax mRNA and protein expression was increased while Bcl-2 mRNA and protein expression was significantly decreased following exposure to DHA compared with the control group (Fig. 2C-E) . In Jurkat cells, DHA induced a 4.72-fold increase in the ratio of Bax/Bcl-2 mRNA compared with the control group and increased the ratio of Bax/Bcl-2 protein expression by over 2-fold. In HuT-78 cells treated with DHA, the ratio of Bax/Bcl-2 mRNA and protein expression increased by 6.08-fold and 3.39-fold, respectively, compared with the control group (Fig. 2F) .
DHA enhances c-Myc phosphorylation at threonine 58 in
Jurkat and HuT-78 cells. To determine whether DHA exerted any effect on c-Myc mRNA levels, the relative expression of c-Myc mRNA was detected by RT-qPCR (Fig. 3A) . It was revealed that c-Myc mRNA expression was downregulated in Jurkat cells treated with 15 µM DHA and HuT-78 cells treated with 30 µM DHA. The differences were statistically significant compared with the control groups (P<0.001).
To determine whether DHA exhibited any effect on c-Myc protein levels, c-Myc protein and c-Myc phosphorylated at threonine 58 expression levels were determined by western blot analysis. The expression level of phosphorylated c-Myc at threonine 58 was increased following DHA treatment for 2 h, while the total relative expression of c-Myc oncoprotein was markedly decreased in Jurkat and HuT-78 cells following treatment with DHA for 48 h (Fig. 3B and C) . The differences in expression levels were significant compared with the control groups (P<0.05). DHA did not have a significant effect on the expression level of GSK3β protein (P>0.05; Fig. 3B ).
DHA decreases p-Akt and p-GSK3β expression in Jurkat and
HuT-78 cells. To detect the effect of DHA on the Akt/GSK3β signaling pathway in Jurkat and HuT-78 cells, Akt and GSK3β mRNA expression levels were examined by RT-qPCR, and Akt, Akt phosphorylated at serine 473, GSK3β and GSK3β phosphorylated at serine 9 protein expression levels were examined by western blot analysis (Fig. 4A-C) . DHA had no effect on the level of Akt and GSK3β mRNA expression or the total protein expression of Akt and GSK3β (Fig. 4A-C) . However, DHA treatment for 6 h resulted in decreased levels of Akt phosphorylated at serine 473 and GSK3β phosphorylated at serine 9 (P<0.001; Fig. 4B and C) .
Discussion
T-cell lymphoma is a common hematological malignancy, and its occurrence is associated with alterations in critical genes and activation of pivotal signaling pathways (5) . High expression of c-Myc is associated with the occurrence and development of lymphoma (7). In addition, the Akt/GSK3β signaling pathway serves a critical role in the regulation of tumor cellular processes, including proliferation, differentiation and apoptosis (7, 9) . DHA is an effective drug in treating patients with malaria (22) . Recent studies have revealed that DHA has antitumor activity with few side effects in various types of tumors in vivo and in vitro (16) (17) (18) (23) (24) (25) . Based on the results of these aforementioned studies, the present study investigated the therapeutic role of DHA and its underlying mechanism in T-cell lymphoma cells.
In the present study, DHA inhibited the proliferation of T-cell lymphoma cells in a concentration-and time-dependent manner. The results of the present study were consistent with those of previous studies in Jurkat and ovarian cancer cells (16, 18) . When different concentrations of DHA were compared, it was revealed that Jurkat cells were more sensitive to DHA than HuT-78 cells. These results indicated that DHA may be a promising drug for treatment in T-lymphoma cells. However, the effect of DHA on the patient samples and xenograft mouse model in T-cell lymphoma were not assessed in the present study; therefore, we will further investigate the effect of DHA in future in vivo studies.
The results of the present study demonstrated that DHA reduced c-Myc protein expression by two potential mechanisms. To begin with, DHA treatment caused a decrease in the c-Myc mRNA level, resulting in a decreased c-Myc protein expression. Additionally, DHA enhanced the phosphorylation of c-Myc at threonine 58, which may trigger c-Myc oncoprotein degradation in T-cell lymphoma cells by the ubiquitin proteasome system. A previous study revealed that DHA promoted c-Myc oncoprotein degradation in HL-60 and HCT116 cells (19) . This suggested that DHA-induced phosphorylation of c-Myc at threonine 58 targets c-Myc for degradation. Taken together, the results of the present study suggested that DHA suppressed c-Myc protein expression at the transcriptional and post-transcriptional level, leading to inhibition of cell proliferation and induction of cell apoptosis.
The Akt/GSK3β signaling pathway serves an important role in the regulation of cell proliferation and apoptosis in cancer. The Akt/GSK3β signaling pathway is activated upon phosphorylation of Akt and GSK3β at serine 473 and serine 9, respectively, and promotes proliferation and inhibits apoptosis. Previous studies have demonstrated that DHA could inhibit the Akt/GSK3β signaling pathway in lung cancer and glioma cells (23, 25) . To further elucidate the mechanism of DHA treatment in T-cell lymphoma cells, the present study investigated the effect of DHA on the Akt/GSK3β signaling pathway. The results of the present study revealed that DHA could suppress the Akt/GSK3β signaling pathway through a process that involved reduction of p-Akt and p-GSK3β expression levels, but did not impact GSK3β steady-state levels.
The Bcl-2 protein is an anti-apoptotic factor that serves a critical role in apoptosis, whereas Bax functions as a pro-apoptotic effector (26). The results of the present study demonstrated that DHA-induced apoptosis was accompanied by the downregulation of anti-apoptotic Bcl-2 expression and the upregulation of pro-apoptotic Bax expression, suggesting that DHA exerts its effects of inducing apoptosis by modulating Bax/Bcl-2 expression levels in T-cell lymphoma cells.
Previous studies have demonstrated that Bcl-2 could abrogate c-Myc-induced apoptosis (27) , and that c-Myc may synergize with Akt in cell growth and proliferation (28) . These studies indicated that c-Myc cooperates with Akt and Bcl-2 to promote tumor progression. These results combined with those of the present study further suggested that the DHA-induced apoptotic effect may also involve DHA reducing Bcl-2 expression and relieving its inhibition of c-Myc. DHA also reduces the expression of c-Myc and p-Akt, leading to the suppression of Jurkat and HuT-78 cell growth and proliferation.
In conclusion, the results of the present study suggested that DHA decreased c-Myc protein expression levels at the transcriptional level and triggered c-Myc degradation by enhancing the phosphorylation of c-Myc at threonine 58 to inhibit cell proliferation and increase cell apoptosis. Furthermore, DHA blocked cell proliferation by suppressing the Akt/GSK3β signaling pathway and reducing c-Myc protein expression, and DHA also induced apoptosis by increasing the ratio of Bax/Bcl-2 in T-cell lymphoma cells. The results of the present study aid in clarifying the mechanism of DHA antitumor activity in T-cell lymphoma cells.
